ALERT: Practice Announcement 2/11/25 – Practice Announcement: We will be OPEN on time on Wednesday, February 12, 2025. Please be safe and allow extra time. Thank you.      Exciting News! Our Gainesville Office has moved to Bristow9450 Innovation Drive, Manassas, VA 20110.  Same great providers and care team, same exceptional care, new, larger space to better serve our patients.

anti-FGFR2 monoclonal antibody FPA144

A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth factor receptor type 2b (FGFR2b), with potential antineoplastic activity. Upon administration, the anti-FGFR2 antibody FPA144 specifically binds to and inhibits FGFR2b on tumor cell surfaces, which prevents FGFR2 from binding to its ligands, FGFR2b activation and the activation of FGFR2b-mediated signal transduction pathways. The binding of FPA144 to FGFR2b protein also induces antibody-dependent cell-mediated cytotoxicity (ADCC) against FGFR2b-expressing tumor cells. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2b, a specific isoform of the receptor tyrosine kinase FGFR2 upregulated in many tumor cell types, is essential to tumor proliferation, differentiation and survival. Glycoengineering enhances the FPA144-mediated ADCC. Check for active clinical trials using this agent. (NCI Thesaurus)

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More